Literature DB >> 16818626

Epigenetic silencing of the PTEN gene in melanoma.

Alireza Mirmohammadsadegh1, Alessandra Marini, Sandeep Nambiar, Mohamed Hassan, Andrea Tannapfel, Thomas Ruzicka, Ulrich R Hengge.   

Abstract

Phosphatase and tensin homologue deleted from chromosome 10 (PTEN) seems to be an important tumor suppressor gene in melanoma. Because the PTEN gene is only infrequently deleted or mutated, and because the PTEN protein is low to absent in a significant number of melanomas, we investigated alternative methods of epigenetic silencing. We did quantitative positional methylation analysis (pyrosequencing) on 37 sera from melanoma patients and on 21 pairs of corresponding sera and melanoma specimens in addition to Taqman reverse transcription-PCR. We report significant positional PTEN promoter methylation in 62% of circulating DNA isolated from sera of patients with metastatic melanoma. The percentage of methylation of a selected CpG island in blood showed a correlation with methylation levels in the corresponding melanoma tissue. Moreover, high percentages of PTEN methylation were associated with low PTEN transcription levels. Using the demethylation agent 5-aza-2'-deoxycytidine, reduced methylation and a corresponding increase in PTEN protein were observed in BLM melanoma cells, leading to reduced AKT activity in an in vitro kinase assay. In summary, epigenetic PTEN silencing seems to be a relevant mechanism of inactivating this tumor suppressor gene in melanoma that may promote melanoma development by derepression of the AKT pathway.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16818626     DOI: 10.1158/0008-5472.CAN-06-0384

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  97 in total

1.  Selenium-containing histone deacetylase inhibitors for melanoma management.

Authors:  Raghavendra Gowda; Subbarao V Madhunapantula; Dhimant Desai; Shantu Amin; Gavin P Robertson
Journal:  Cancer Biol Ther       Date:  2012-06-06       Impact factor: 4.742

Review 2.  Genetic alterations of PTEN in human melanoma.

Authors:  Almass-Houd Aguissa-Touré; Gang Li
Journal:  Cell Mol Life Sci       Date:  2011-11-11       Impact factor: 9.261

Review 3.  Circulating epigenetic biomarkers in melanoma.

Authors:  Yu Xin; Zheng Li; Matthew T V Chan; William Ka Kei Wu
Journal:  Tumour Biol       Date:  2015-12-11

4.  PTEN gene is infrequently hypermethylated in human esophageal squamous cell carcinoma.

Authors:  Zhenguo Sun; Na Ji; Mingming Bi; Shuai Wang; Xiangyan Liu; Zhou Wang
Journal:  Tumour Biol       Date:  2015-02-28

Review 5.  Techniques used in studies of epigenome dysregulation due to aberrant DNA methylation: an emphasis on fetal-based adult diseases.

Authors:  Shuk-mei Ho; Wan-yee Tang
Journal:  Reprod Toxicol       Date:  2007-01-19       Impact factor: 3.143

6.  Rapid identification of promoter hypermethylation in hepatocellular carcinoma by pyrosequencing of etiologically homogeneous sample pools.

Authors:  Emelyne Dejeux; Virginie Audard; Catherine Cavard; Ivo Glynne Gut; Benoit Terris; Jörg Tost
Journal:  J Mol Diagn       Date:  2007-08-09       Impact factor: 5.568

Review 7.  Growth factors and oncogenes as targets in melanoma: lost in translation?

Authors:  Lawrence Kwong; Lynda Chin; Stephan N Wagner
Journal:  Adv Dermatol       Date:  2007

8.  Activation of the AKT and mammalian target of rapamycin pathways and the inhibitory effects of rapamycin on those pathways in canine malignant melanoma cell lines.

Authors:  Michael S Kent; Cameron J Collins; Fang Ye
Journal:  Am J Vet Res       Date:  2009-02       Impact factor: 1.156

9.  A tumor suppressor function for the lipid phosphatase INPP4B in melanocytic neoplasms.

Authors:  Rolando Perez-Lorenzo; Kamraan Z Gill; Che-Hung Shen; Feng X Zhao; Bin Zheng; Hans-Joachim Schulze; David N Silvers; Georg Brunner; Basil A Horst
Journal:  J Invest Dermatol       Date:  2013-11-28       Impact factor: 8.551

Review 10.  Genetics of metastasis: melanoma and other cancers.

Authors:  Noel Turner; Olivia Ware; Marcus Bosenberg
Journal:  Clin Exp Metastasis       Date:  2018-05-02       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.